Financial Review of Nektar Therapeutics (NASDAQ:NKTR)

10

Quarterly Sales and EPS Roundup:

Nektar Therapeutics (NKTR) reported sales (ttm) of 165.4 Million, whereas, 7 number of analysts estimated the mean sale of 53.71 million. The analysts estimated sales for the higher end at 74.82 million and lower end at 42.6 million while the year ago reported sale was 57.23 million.

7 number of analysts have estimated the sales of the company for the quarter ending May 1, 2017- May 5, 2017, analysts estimated mean sale target of 54.13 million while high and low sale targets are estimated at 129.34 million and 35.7 million respectively.

Nektar Therapeutics (NKTR) reported earning per shares for the quarter ending Mar 01 AMC at -0.28, whereas, 7 number of analysts estimated the mean EPS at -0.25. The analysts estimated EPS for the higher end at -0.07 and lower end at -0.33 while the year ago reported earnings per share was -0.21.

The company has mean EPS estimate of -0.23 reported by 7 number of analyst for the quarter ending May 1, 2017- May 5, 2017. The analysts estimated mean EPS at -0.23 while the high and low EPS estimate stand at 0.26 and -0.35 respectively. In contrast to the year ago quarter EPS was at -0.21.

Valuation Ratios of Nektar Therapeutics (NKTR) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Nektar Therapeutics (NKTR). These ratios are important while doing valuation of the company or the shares of the company.

Nektar Therapeutics (NKTR) currently has P/E (Price to Earnings) ratio of 0 while the company’s industry has 54.04 P/E and the sector P/E is 29.67. Similarly, the company’s last 5 years high P/E ratio is 0 and low P/E is 0, whereas, the industry’s and sector’s  high P/E for the past year is 174.55 and 44.5 respectively and low P/E ratio for the last 5 years is 79.42 for the industry and 23.02 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, NKTR has Beta of 1.69 while its industry and Sector’s beta remains at 0.93 and 0.82 respectively.

Price to Sale ratio of NKTR stands at 17.3 while Price to Book Ratio stands at 32.35. Its Price to Cash Flow ratio shows the value of 0, whereas, the industry and sector ratio of Price to Cash Flow ticked at 74.04 and 22.87 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Nektar Therapeutics (NKTR) stands at 18.27 while the industry’s and the sector’s growth for next 5 years ticked at 21.02 and 10.73 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 0 and -8.04.

Nektar Therapeutics (NKTR) Trading Statistics:

The company surged 2.79% and closed its last trading session at $18.61. The market capitalization of the company is at $2.94 Billion. The stock touched 52-week High of $24.88 on 03/29/17 and 52-week Low of $11.41 on 01/31/17. The stock currently has Weekly Volatility of 3.90% and Monthly Volatility of 5.02%. The Beta for the company stands at 1.71 and its Average True Range (ATR) shows a value of 1.09.

 

SHARE